High SNORA12 expression was associated with poor prognosis in glioma (HR = 1.31, <i>p</i> = 0.006) but favorable outcomes in pancreatic (HR = 0.51, <i>p</i> = 0.01) and breast cancer (HR = 0.56, <i>p</i> = 0.02). This evidence concerns the gene SNORA12 and central nervous system cancer.